Literature DB >> 16821276

Anti-tumor necrosis factor-alpha-induced psoriasis.

Ismail Sari1, Servet Akar, Merih Birlik, Banu Sis, Fatos Onen, Nurullah Akkoc.   

Abstract

We describe a patient with rheumatoid arthritis who developed psoriasis during treatment with etanercept; psoriatic lesions resolved completely after the drug was discontinued, but returned on rechallenge. No such adverse skin reaction occurred after switching therapy to infliximab. Through a Medline search we identified 11 reports involving 32 patients who developed psoriasis/psoriasiform eruptions during therapy with tumor necrosis factor-alpha (TNF-alpha) inhibitors. All TNF-alpha blocking agents have been reported to lead to or exacerbate psoriasis. In some cases skin changes were severe enough to discontinue the medication.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16821276

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Risks and benefits of biologic therapy for inflammatory bowel diseases.

Authors:  Geert D'Haens
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

2.  Psoriasis and psoriasiform lesions induced by TNFα antagonists: the experience of a tertiary care hospital from northern Spain.

Authors:  Alejandra López-Robles; Rubén Queiro; Mercedes Alperi; Sara Alonso; José L Riestra; Javier Ballina
Journal:  Rheumatol Int       Date:  2011-12-21       Impact factor: 2.631

3.  Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.

Authors:  T Cabaleiro; R Prieto-Pérez; R Navarro; G Solano; M Román; D Ochoa; F Abad-Santos; E Daudén
Journal:  Pharmacogenomics J       Date:  2015-07-21       Impact factor: 3.550

4.  Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine.

Authors:  Spyros Aslanidis; Athina Pyrpasopoulou; Stella Douma; Areti Triantafyllou
Journal:  Clin Rheumatol       Date:  2007-11-10       Impact factor: 2.980

Review 5.  TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification.

Authors:  Lauren M Workman; Hasem Habelhah
Journal:  Cell Signal       Date:  2013-04-21       Impact factor: 4.315

6.  Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.

Authors:  Martin Schulz; Helmut Dotzlaw; Gunther Neeck
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

7.  The changing face of spondyloarthropathies under TNF α blockade.

Authors:  Ori Elkayam; Irena Litinsky; David Levartovsky; Dan Caspi
Journal:  Open Rheumatol J       Date:  2008-11-14

8.  Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  M J Harrison; W G Dixon; K D Watson; Y King; R Groves; K L Hyrich; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2008-04-02       Impact factor: 19.103
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.